Small molecules and peptides that interfere with AP-1 DNA binding or dimer formation are being investigated as therapeutics [150, 151] and these could be attractive treatments for cHL and ALK+ ALCL. This evidence concerns the gene JUNB and anaplastic large cell lymphoma.